New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 25, 2013
10:11 EDTWPZ, OC, TGP, BP, TDW, NBL, BRY, ABAX, HNZ, ALU, DVAX, DEPO, SM, GLF, ASNA, TEVA, CBSH, PLCE, PETM, NVE, ENDP, AROOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Abaxis (ABAX) downgraded to Underperform from Neutral at BofA/Merrill... Aeropostale (ARO) downgraded to Hold from Buy at KeyBanc... Affymax (AFFY) downgraded to Neutral from Outperform at RW Baird... Ascena Retail (ASNA) downgraded to Hold from Buy at KeyBanc... Berry Petroleum (BRY) downgraded to Neutral from Positive at Susquehanna... Endo Health (ENDP) downgraded to Underweight from Neutral at Piper Jaffray... GulfMark Offshore (GLF) downgraded to Buy from Strong Buy at ISI Group... NV Energy (NVE) downgraded to Hold from Buy at Wunderlich... Noble Energy (NBL) downgraded to Buy from Conviction Buy at Goldman... SM Energy (SM) downgraded to Market Perform from Outperform at BMO Capital... Tidewater (TDW) downgraded to Neutral from Buy at ISI Group... PetSmart (PETM) downgraded to Equal Weight from Overweight at Johnson Rice... Depomed (DEPO) downgraded to Hold from Buy at WallachBeth... BP (BP) downgraded to Buy from Strong Buy at ISI Group... Children's Place (PLCE) downgraded at Janney Capital... Dynavax (DVAX) downgraded to Hold from Buy at MLV Equity... Teekay LNG (TGP) downgraded at Raymond James... Commerce Bancshares (CBSH) downgraded at Raymond James... Alcatel-Lucent (ALU) downgraded to Underweight from Neutral at HSBC... Teva (TEVA) downgraded to Hold from Buy at Argus... Owens Corning (OC) downgraded to Market Perform from Outperform at Wells Fargo... Heinz (HNZ) downgraded to Neutral from Buy at Citigroup... Williams Partners (WPZ) downgraded to Accumulate from Buy at Global Hunter.
News For ABAX;ARO;ASNA;BRY;ENDP;GLF;NBL;NVE;SM;TDW;PETM;DEPO;BP;PLCE;DVAX;TGP;CBSH;ALU;OC;TEVA;HNZ;WPZ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
January 21, 2015
17:19 EDTENDPBoston Beer to replace Endo in S&P 400 as of 1/26 close
Subscribe for More Information
17:18 EDTENDPEndo to replace Covidien in S&P 500 as of 1/26 close
13:43 EDTBPOPEC El-Badri says oil will bounce back, not drop to $20, Bloomberg reports
Subscribe for More Information
08:38 EDTTEVAMomenta announces Supreme Court decision to remand generic Copaxone back to CAFC
Subscribe for More Information
05:48 EDTBPStocks with implied volatility movement; IWM BP
Subscribe for More Information
January 20, 2015
17:56 EDTBPBP judge may allow installment payments on penalty, WSJ says
Subscribe for More Information
14:37 EDTTEVATeva generic competition to Copaxone pushed out by ruling, says BMO Capital
Subscribe for More Information
12:56 EDTTEVAMylan says continues to believe '808 patent is 'invalid'
Subscribe for More Information
11:29 EDTTEVATeva says Supreme Court reverses circuit court judgment on Copaxone 20 mg/mL
Teva Pharmaceutical announced the U.S. Supreme Court’s decision in Teva Pharmaceuticals USA, Inc. et al. Petitioners v. Sandoz Inc. et al. that reversed the Federal Circuit Court’s judgment of invalidity of Teva’s ‘808 patent for COPAXONE 20 mg/mL. The Supreme Court remanded the case to the Federal Circuit for further review in light of the applicable standard the Supreme Court laid out for appellate review of claim construction. A ruling last year by the U.S. Court of Appeals for the Federal Circuit upheld four Teva patents that expired in May 2014, while invalidating the ‘808 patent that is set to expire on September 1, 2015. “We are encouraged by the U.S. Supreme Court’s Decision and look forward to the Federal Circuit’s review. We will continue to explore all available avenues to protect our intellectual property for COPAXONE 20mg/mL,” said Erez Vigodman, President and CEO of Teva. “There is currently no FDA-approved follow-on version of Teva’s COPAXONE. We are encouraged by the FDA’s willingness to date to have dialogue regarding the complexities of COPAXONE 20 mg/mL and the potential limitations and other unknowns of purported follow-on versions,” added Rob Koremans, MD, President and CEO of Global Specialty Medicines at Teva.
10:45 EDTTEVATeva spikes, retraces, after win in Copaxone patent case
Subscribe for More Information
10:40 EDTTEVAMomenta Pharma sinks after Supreme Court rules on Copaxone
Subscribe for More Information
10:35 EDTTEVATeva rises after patent ruling upheld by Supreme Court
The Supreme Court upheld a lower court ruling related to generic versions of Teva's Copaxone drug. In the ruling, the court wrote that "When reviewing a district court’s resolution of subsidiary factual matters made in the course of its construction of a patent claim, the Federal Circuit must apply a “clear error,” not a de novo, standard of review." Teva shares are up 1.5% to $58.58 in early trading after the ruling. Reference Link
09:18 EDTDEPOJohnson & Johnson CEO says core businesses 'strong'
Johnson & Johnson (JNJ) providing sustainable, high quality healthcare "one of society's greatest challenges." Says core businesses "strong," positioned to continue expanding their leadership positions. CEO Alex Gorsky says company is changing the way it interacts with customers, evolving to be more "effective," "efficient." Says U.S. OTC consent decree requirements completed. Says in the process of developing a China lung center. Says still plans to take $1B out of P&L in next three years. Says aims to bring Ebola vaccine to market "as fast as possible." Says "well-positioned" for long-term. Says currency headwinds have increased "quite substantially," negatively impacting sales, earnings to greater extent than company had anticipated. Sees Depomed (DEPO) transaction closing in Q2. Expects R&D tax credit will be renewed in 2015. If R&D tax credit is approved, sees effective tax rate for 2015 of approx. 20%-21%. Sees operational sales growth for 2015 approx. 6%. Says Wall Street forecasts may not adequately reflect likely negative impact in 2015 of foreign exchange. Sees FY15 operational sales growth 1%-2% in constant currency. Comments made on the Q4 earnings conference call.
08:09 EDTABAXAbaxis receives approval for its VetScan FeLV-FIV Rapid Test Kit
Subscribe for More Information
07:43 EDTNBLNoble Energy reports no commercial hydrocarbons in Madison exploration well
Noble Energy announced that the Madison exploration well in the Gulf of Mexico reached the targeted Upper and Middle Miocene objectives and did not encounter commercial hydrocarbons. Drilled to a total depth of 16,859 feet on Mississippi Canyon 479, the well has been plugged and abandoned and the drilling rig has been released. Noble Energy operated the well with a 60% working interest and Stone Energy Offshore, had the remaining 40%.
07:00 EDTENDPEndo price target raised to $98 from $86 at Piper Jaffray
Piper Jaffray raised its price target for Endo shares to $98 saying Xiaflex's market expansion opportunities are not fully appreciated by the broader market. It keeps an Overweight rating on the stock.
January 19, 2015
06:47 EDTBPJPMorgan says oil may drop below $40/barrel in near-term
Subscribe for More Information
January 18, 2015
18:32 EDTBPBP will cite crude price decline in Gulf spill fine determination, WSJ says
BP, which is facing up to $13.7B in federal fines, is set to go to trial on January 20 in federal court in New Orleans to determine the amount it must pay the U.S. government for each barrel of crude that spilled into the Gulf during the 2010 Deepwater Horizon disaster, says the Wall Street Journal. BP's lawyers plan to use the recent plunge in oil prices in their arguments before the court and will likely cite a weakened BP Exploration & Production, the subsidiary that is charged with the spill violations, added the Wall Street Journal. Reference Link
18:11 EDTBPAnadarko faces pollution penalty in Deepwater Horizon disaster, WSJ says
Subscribe for More Information
14:22 EDTBPSchlumberger boss says oil price to challenge land producers, WSJ says
Paal Kibsgaard, CEO of Schlumberger, said U.S. energy producers are not done with work force reductions and that because of high costs, producers that focus on shale fields are worse off than rivals, says the Wall Street Journal. Publicly traded companies in the space include BP (BP), Chevron (CVX), ConocoPhillips (COP), Exxon Mobil (XOM), Royal Dutch Shell (RDS.A), Total (TOT), Schlumberger (SLB) and Baker Hughes (BHI). Reference Link
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use